Reviva Pharmaceuticals (NASDAQ:RVPH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Reviva Pharmaceuticals (NASDAQ:RVPH) to a sell rating in a research note issued to investors on Saturday morning.

A number of other research analysts also recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Reviva Pharmaceuticals in a research note on Tuesday, December 23rd. Chardan Capital reiterated a “buy” rating and issued a $40.00 price objective on shares of Reviva Pharmaceuticals in a research note on Monday, January 5th. D. Boral Capital downgraded Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 5th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Reviva Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $66.67.

Reviva Pharmaceuticals Price Performance

NASDAQ RVPH opened at $2.57 on Friday. The company has a fifty day moving average of $5.32 and a two-hundred day moving average of $8.41. The company has a market capitalization of $15.01 million, a PE ratio of -0.28 and a beta of 0.10. Reviva Pharmaceuticals has a 1 year low of $2.37 and a 1 year high of $23.40.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC purchased a new stake in Reviva Pharmaceuticals during the 1st quarter valued at approximately $58,000. Geode Capital Management LLC grew its stake in shares of Reviva Pharmaceuticals by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after purchasing an additional 29,063 shares during the last quarter. Persistent Asset Partners Ltd increased its holdings in shares of Reviva Pharmaceuticals by 300.0% in the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock valued at $244,000 after purchasing an additional 480,864 shares during the period. XTX Topco Ltd acquired a new position in shares of Reviva Pharmaceuticals in the second quarter valued at approximately $31,000. Finally, Armistice Capital LLC purchased a new stake in shares of Reviva Pharmaceuticals during the second quarter worth approximately $1,026,000. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.